Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial.

Saved in:
Bibliographic Details
Title: Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial.
Authors: Lampa J; Department of Medicine, Rheumatology Unit, Centre for Molecular Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden. Electronic address: on.lampa@ki.se., Nordström D; Departments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland., van Vollenhoven R; Department of Medicine, Rheumatology Unit, Centre for Molecular Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden; Amsterdam Rheumatology and Immunology Center, Reade, Netherlands., Lund Hetland M; Copenhagen Center for Arthritis Research and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark., Haavardsholm EA; REMEDY, Diakonhjemmet Hospital, Oslo, Norway., Østergaard M; Copenhagen Center for Arthritis Research and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark., Rudin A; Rheumatology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden., Heiberg MS; REMEDY, Diakonhjemmet Hospital, Oslo, Norway., Nurmohamed M; Amsterdam Rheumatology and Immunology Center, Reade, Netherlands; Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam, Netherlands., Gudbjornsson B; Landspitali University Hospital, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, Iceland., Lend K; Department of Medicine, Rheumatology Unit, Centre for Molecular Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden., Hørslev-Petersen K; Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark., Sokka-Isler T; Department of Medicine and University of Eastern Finland, Jyväskylä Central Hospital, Jyväskylä, Finland., Gröndal G; Landspitali University Hospital, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, Iceland., Krabbe S; Copenhagen Center for Arthritis Research and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark., Lindqvist J; Department of Medicine, Rheumatology Unit, Centre for Molecular Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden., Gjertsson I; Rheumatology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden., Glinatsi D; Department of Rheumatology, Skaraborg Hospital, Skovde, Sweden., Kapetanovic M; Section of Rheumatology, Department of Clinical Sciences Lund, Skåne University Hospital, Lund and Malmö, Sweden., Gentline C; Department of Medicine, Rheumatology Unit, Centre for Molecular Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden., Aga AB; REMEDY, Diakonhjemmet Hospital, Oslo, Norway., Relas H; Departments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland., Lorenzen T; Department of Rheumatology, Silkeborg University Hospital, Silkeborg, Denmark., Cagnotto G; Section of Rheumatology, Department of Clinical Sciences Malmö, Lund University, Skåne University Hospital, Sweden., Back J; Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden., Hendricks O; Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark., Dijkshoorn B; Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam, Netherlands., Öberg K; Department of Rheumatology, Falu Hospital, Falun, Sweden., Ljoså MK; Department of Rheumatology, Ålesund Hospital, Ålesund, Norway., Brodin E; Department of Rheumatology, Haukeland University Hospital, Bergen, Norway., Lindegaard HM; Rheumatology Research Unit, Odense University Hospital, Southern University of Denmark, Denmark., Söderbergh A; Department of Rheumatology, Örebro University Hospital, Örebro, Sweden., Rizk M; Rheumatology Clinic, Västmanlands Hospital Västerås, Sweden., Kastbom A; Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Clinical Department of Rheumatology in Östergötland, Region Östergötland, Linköping, Sweden., Larsson P; Academic Specialist Center, Stockholm, Sweden., Uhrenholt L; Center of Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark., Just SA; Department of Rheumatology, Odense Universitetshospital, Odense, Denmark; Section of Rheumatology, Department of Medicine, Svendborg Hospital OUH, Denmark., Stevens DJ; Department of Rheumatology, St Olav's Hospital, University Hospital of Trondheim, Trondheim, Norway., Laurberg TB; Department of Rheumatology, Aarhus University Hospital, Denmark., Bakland G; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway., Olsen IC; Department of Research Support for Clinical Trials, Oslo University Hospital, Oslo, Norway., Sexton J; REMEDY, Diakonhjemmet Hospital, Oslo, Norway., Uhlig T; REMEDY, Diakonhjemmet Hospital, Oslo, Norway.
Corporate Authors: NORD-STAR study group
Source: The Lancet. Rheumatology [Lancet Rheumatol] 2026 Apr; Vol. 8 (4), pp. e285-e294.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101765308 Publication Model: Print Cited Medium: Internet ISSN: 2665-9913 (Electronic) Linking ISSN: 26659913 NLM ISO Abbreviation: Lancet Rheumatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2665-9913
DOI:10.1016/S2665-9913(26)00007-X